{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:58:41Z","timestamp":1790787521399,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cutaneous leishmaniasis (CL) is a protozoan parasitic infection caused by Leishmania species and transmitted through the bite of infected sandflies. The disease is endemic in tropical, subtropical and Mediterranean regions, where it presents as localized skin ulcers, often leaving scars that can lead to significant morbidity and social stigma. This review focuses on the aetiopathogenesis, epidemiology, clinical features, management strategies and research gaps in CL. Understanding the complex immune response involved in the pathogenesis of CL, as well as the environmental and socio-economic factors driving its spread, is critical for designing effective control measures. Clinical presentation varies from simple ulcers to more complex forms like mucocutaneous leishmaniasis. Management primarily involves antimicrobial therapy, with treatments such as miltefosine, antimony compounds and liposomal amphotericin B being the mainstays, although drug resistance is emerging as a significant challenge. Research gaps remain in the development of effective vaccines, better diagnostic tools and alternative treatments. Addressing these gaps will improve patient health outcomes and facilitate the elimination of CL in endemic regions.<\/jats:p>","DOI":"10.1093\/ced\/llaf548","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:06:46Z","timestamp":1765544806000},"page":"1225-1234","source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous leishmaniasis: aetiopathogenesis, epidemiology, clinical features, management and\u00a0research\u00a0gaps"],"prefix":"10.1093","volume":"51","author":[{"given":"Wendemagegn","family":"Enbiale","sequence":"first","affiliation":[{"name":"Department of Dermatology, Bahir Dar University , Bahir Dar ,","place":["Ethiopia"]},{"name":"Collaborative Research and Training Center for Neglected Tropical Diseases, Arba Minch University , Arba Minch ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Dassoni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Desio Hospital , Desio, MB ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"2026062510021077200_llaf548-B1","author":"World Health Organization. Leishmaniasis","year":"12  2023"},{"key":"2026062510021077200_llaf548-B2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.annder.2019.02.002","article-title":"Cutaneous leishmaniasis","volume":"146","author":"Mokni","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"2026062510021077200_llaf548-B3","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3855\/jidc.6833","article-title":"Recent updates and perspectives on leishmaniasis","volume":"9","author":"Savoia","year":"2015","journal-title":"J Infect Dev Ctries"},{"key":"2026062510021077200_llaf548-B4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.11138\/cderm\/2017.5.1.012","article-title":"Cutaneous leishmaniasis and its clinical spectrum. An overview from the Old World","volume":"5","author":"Dassoni","year":"2017","journal-title":"Clin Dermatol"},{"key":"2026062510021077200_llaf548-B5","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/ijd.16265","article-title":"Burden and risk factors of cutaneous leishmaniasis in Ethiopia: a systematic review and meta-analysis","volume":"61","author":"Shita","year":"2022","journal-title":"Int J Dermatol"},{"key":"2026062510021077200_llaf548-B6","volume-title":"Guideline for diagnosis, treatment and prevention of leishmaniasis in Ethiopia","author":"Federal Ministry of Health Ethiopia and World Health Organization","year":"2013","edition":"2nd edn"},{"key":"2026062510021077200_llaf548-B7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s13071-023-06057-9","article-title":"First report of cutaneous leishmaniasis caused by Leishmania donovani in Ethiopia","volume":"16","author":"Amare","year":"2023","journal-title":"Parasites Vectors"},{"key":"2026062510021077200_llaf548-B8","first-page":"285","article-title":"Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014","volume":"22","author":"World Health Organization","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"2026062510021077200_llaf548-B9","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLOS ONE"},{"key":"2026062510021077200_llaf548-B10","first-page":"653","article-title":"Global leishmaniasis surveillance updates 2023: 3\u2005years of the NTD road map","volume":"45","author":"Jain","year":"2024","journal-title":"Wkly Epidemiol Rec"},{"issue":"Suppl. 1","key":"2026062510021077200_llaf548-B11","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijantimicag.2010.06.023","article-title":"Leishmaniasis in the World Health Organization Eastern Mediterranean Region","volume":"36","author":"Postigo","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2026062510021077200_llaf548-B12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.pt.2006.09.004","article-title":"Leishmaniasis and poverty","volume":"22","author":"Alvar","year":"2006","journal-title":"Trends Parasitol"},{"key":"2026062510021077200_llaf548-B13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cmi.2019.06.022","article-title":"Profiling infectious diseases in Turkey after the influx of 3.5 million Syrian refugees","volume":"26","author":"Erg\u00f6n\u00fcl","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026062510021077200_llaf548-B14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14787210.2016.1177457","article-title":"The Syrian conflict and infectious diseases","volume":"14","author":"Ozaras","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026062510021077200_llaf548-B15","author":"Labpedia.net"},{"key":"2026062510021077200_llaf548-B16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40257-022-00726-8","article-title":"Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments","volume":"23","author":"De Vries","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026062510021077200_llaf548-B17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1051\/parasite\/1990653111","article-title":"Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification","volume":"65","author":"Rioux","year":"1990","journal-title":"Ann Parasitol Hum Comp"},{"key":"2026062510021077200_llaf548-B18","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ijpara.2007.04.003","article-title":"Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies","volume":"37","author":"Bates","year":"2007","journal-title":"Int J Parasitol"},{"key":"2026062510021077200_llaf548-B19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"2026062510021077200_llaf548-B20","first-page":"293","volume-title":"Antibiotic and Antifungal Therapies in Dermatology","author":"Van Hees","year":"2016"},{"key":"2026062510021077200_llaf548-B21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3855\/jidc.15979","article-title":"Clinical pattern and treatment outcome of cutaneous leishmaniasis in two hospitals in Bahir Dar, Ethiopia (2017\u20132021)","volume":"16","author":"Tesfa","year":"2022","journal-title":"J Infect Dev Ctries"},{"key":"2026062510021077200_llaf548-B22","volume-title":"Guidelines for case management of cutaneous leishmaniasis in Pakistan","author":"K\u00e4mink","year":"2019"},{"key":"2026062510021077200_llaf548-B23","author":"Pan American Health Organization\/World Health Organization"},{"key":"2026062510021077200_llaf548-B24","volume-title":"Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region","author":"World Health Organization","year":"2014"},{"key":"2026062510021077200_llaf548-B25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/ijd.14002","article-title":"Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey","volume":"57","author":"Uzun","year":"2018","journal-title":"Int J Dermatol"},{"key":"2026062510021077200_llaf548-B26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3855\/jidc.511","article-title":"PCR detection of Leishmania in skin biopsies","volume":"3","author":"Lemrani","year":"2009","journal-title":"J Infect Dev Ctries"},{"key":"2026062510021077200_llaf548-B27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13643-023-02422-y","article-title":"Diagnostic performance of CL Detect rapid-immunochromatographic test for cutaneous leishmaniasis: a systematic review and meta-analysis","volume":"12","author":"Gebremeskele","year":"2023","journal-title":"Syst Rev"},{"key":"2026062510021077200_llaf548-B28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"2026062510021077200_llaf548-B29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben Salah","year":"2013","journal-title":"N Engl J Med"},{"key":"2026062510021077200_llaf548-B30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-4632.2004.02002.x","article-title":"Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis","volume":"43","author":"Asilian","year":"2004","journal-title":"Int J Dermatol"},{"key":"2026062510021077200_llaf548-B31","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1371\/journal.pntd.0000628","article-title":"A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection","volume":"4","author":"Aronson","year":"2010","journal-title":"PLOS Negl Trop Dis"},{"key":"2026062510021077200_llaf548-B32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.actatropica.2007.05.005","article-title":"Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran","volume":"103","author":"Mohebali","year":"2007","journal-title":"Acta Trop"},{"key":"2026062510021077200_llaf548-B33","volume-title":"Manual on case management and surveillance of the leishmaniases in the WHO European region","author":"World Health Organization","year":"2017"},{"key":"2026062510021077200_llaf548-B34","first-page":"adv00322","article-title":"Cutaneous leishmaniasis treated with miltefosine: a case series of 10 paediatric patients","volume":"100","author":"Ollech","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2026062510021077200_llaf548-B35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/00034983.1997.11813217","article-title":"Treatment of \u00adcutaneous leishmaniasis with antimony: intramuscular versus intralesional administration","volume":"91","author":"Alkhawajah","year":"1997","journal-title":"Ann Trop Med Parasitol"},{"key":"2026062510021077200_llaf548-B36","doi-asserted-by":"crossref","first-page":"e0184777","DOI":"10.1371\/journal.pone.0184777","article-title":"Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review","volume":"12","author":"Brito","year":"2017","journal-title":"PLOS ONE"},{"key":"2026062510021077200_llaf548-B37","doi-asserted-by":"publisher","DOI":"10.37774\/9789275125038","volume-title":"Guideline for the treatment of leishmaniasis in the Americas","author":"Pan American Health Organization","year":"2022","edition":"2nd edition"},{"key":"2026062510021077200_llaf548-B38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1179\/000349802125002293","article-title":"Human cutaneous leishmaniasis caused by Leishmania naiffi is wide-spread in South America","volume":"96","author":"Pratlong","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"key":"2026062510021077200_llaf548-B39","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2026062510021077200_llaf548-B40","author":"World Health Organization"},{"key":"2026062510021077200_llaf548-B41","doi-asserted-by":"crossref","first-page":"e0003592","DOI":"10.1371\/journal.pntd.0003592","article-title":"Randomized single-blinded non-inferiority trial of 7\u2005mg\/kg pentamidine isethionate versus 4\u2005mg\/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname","volume":"9","author":"Hu","year":"2015","journal-title":"PLOS Negl Trop Dis"},{"key":"2026062510021077200_llaf548-B42","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3201\/eid1309.061446","article-title":"Recurrent American cutaneous leishmaniasis","volume":"13","author":"Gangneux","year":"2007","journal-title":"Emerg Infect Dis"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf548\/65877324\/llaf548.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/7\/1225\/65877324\/llaf548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/7\/1225\/65877324\/llaf548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:02:30Z","timestamp":1782396150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/7\/1225\/8379535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,12,13]]},"published-print":{"date-parts":[[2026,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf548","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,13]]}}}